How many insider trades does FilingIQ track for MGTX?

FilingIQ tracks 247 Form 4 insider transactions for MGTX (MeiraGTx Holdings plc), covering filings from Jun 8, 2018 onwards. 25 of those were filed in the last 90 days.

Are MGTX insiders net buyers or net sellers?

Across the full Form 4 history for MGTX, 11 transactions (4%) were open-market purchases and 80 (32%) were open-market sales. Compensatory awards and option exercises are filtered out of these counts.

Where does MGTX insider data come from?

Every transaction shown on this page is sourced directly from SEC EDGAR Form 4 filings. FilingIQ parses the raw XML, normalises insider identity across reporting variations, and scores each trade on its multi-factor composite model.

What sector is MGTX in?

MeiraGTx Holdings plc (MGTX) is classified in the Healthcare sector, specifically Biotechnology, with a current market capitalisation of $596.44M.

MGTX insider trading

NasdaqGS Healthcare

MeiraGTx Holdings plc — scored insider trade history from SEC Form 4 filings, parsed and contextualised by FilingIQ.

Total Form 4 trades

247

Last 90 days

Buys / sells

4% / 32%

Market cap

$596.44M

About MeiraGTx Holdings plc

MeiraGTx Holdings plc, a clinical stage genetics medicines company, focusing on developing treatments for patients with serious diseases. The company develops various therapies for ocular diseases, including inherited retinal diseases and large degenerative ocular diseases; neurodegenerative diseases; and xerostomia. It is also developing AAV-AQP1 in Phase 2 trial for radiation-induced grade 2/3 radiation-induced xerostomia, as well as in Phase ½ trial for Sjogren's syndrome; AAV-GAD in Phase 2 trial for Parkinson's disease; AAV-RPE65 in Phase 2 trial for RPE65-associated retinal dystrophy; and AAV-CNGB3 and AAV-CNGA3, which are both in Phase 2 trial for achromatopsia, as well as offers AAV-AIPL1 for Leber congenital amaurosis (LCA) 4. In addition, the company's products under preclinical development include AAV-RDH12 for retinol dehydrogenase 12 mutation-associated retinal dystrophy; AAV-BBS10 for Bardet-Biedl syndrome (BBS) due to BBS10 mutations; AAV-RetGC for LCA type 1; and AAV-UPF1 for amyotrophic lateral sclerosis, as well as programs for Alzheimer's disease, and wet and dry neovascular age related macular degeneration. Further, it provides riboswitch platform for the delivery of metabolic peptides; and cell therapies for oncology, autoimmune disease, and long term intractable pain. The company has collaborations with Johnson & Johnson Innovative Medicine for the research, development, and commercialization of gene therapies for the treatment of inherited retinal disease; and Hologen Limited for the research, development, manufacture, and commercialization of AAV-GAD investigational gene therapy for the treatment of Parkinson's disease, AAV-BDNF investigational gene therapy for genetic obesity disorders, and other genetic medicines to the central nervous system. MeiraGTx Holdings plc was founded in 2015 and is based in New York, New York.

Company website: meiragtx.com

MGTX insider activity at a glance

FilingIQ has scored 247 insider transactions for MGTX since Jun 8, 2018. The most recent filing in our index is dated May 13, 2026.

Across the full history, 11 open-market purchases and 80 open-market sales were filed under transaction codes P and S respectively. Compensatory share awards (code A) and option exercises (code M) are tracked separately and not counted here.

The average FilingIQ composite score on MGTX insider trades is 55.1/100, produced by FilingIQ's multi-factor Form 4 model. Model framework documented at methodology.

View live MGTX trades on FilingIQ Raw filings on SEC EDGAR

Other Healthcare tickers with recent insider activity

UTHR 1,098

UNITED THERAPEUTICS Corp

APLS 279

Apellis Pharmaceuticals, Inc.

KMDA 218

KAMADA LTD

BMY 185

BRISTOL MYERS SQUIBB CO

ADPT 184

Adaptive Biotechnologies Corp

GH 169

Guardant Health, Inc.

ISRG 166

INTUITIVE SURGICAL INC

VTRS 165

Viatris Inc

13F funds holding MGTX

PERCEPTIVE ADVISORS LLC

$85.25M · 3.0% of AUM

JOHNSON & JOHNSON (JNJ)

$54.66M · 10.8% of AUM

Frequently asked

How many insider trades does FilingIQ track for MGTX?: FilingIQ tracks 247 Form 4 insider transactions for MGTX (MeiraGTx Holdings plc), covering filings from Jun 8, 2018 onwards. 25 of those were filed in the last 90 days.
Are MGTX insiders net buyers or net sellers?: Across the full Form 4 history for MGTX, 11 transactions (4%) were open-market purchases and 80 (32%) were open-market sales. Compensatory awards and option exercises are filtered out of these counts.
Where does MGTX insider data come from?: Every transaction shown on this page is sourced directly from SEC EDGAR Form 4 filings. FilingIQ parses the raw XML, normalises insider identity across reporting variations, and scores each trade on its multi-factor composite model.
What sector is MGTX in?: MeiraGTx Holdings plc (MGTX) is classified in the Healthcare sector, specifically Biotechnology, with a current market capitalisation of $596.44M.

Methodology & sources

Every MGTX insider transaction shown on FilingIQ is parsed directly from a public SEC Form 4 XML filing. Insider identity is normalised across reporting variants (CIK changes, name spellings, related-party indirect holdings). The FilingIQ composite score is documented in full on the team page and algo disclosure. Not investment advice; see disclaimer.